City Holding Co. Buys 4,320 Shares of Bristol-Myers Squibb Co. (BMY)
City Holding Co. increased its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 21.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,698 shares of the biopharmaceutical company’s stock after buying an additional 4,320 shares during the period. City Holding Co.’s holdings in Bristol-Myers Squibb were worth $1,332,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Bank of Montreal Can acquired a new position in Bristol-Myers Squibb during the second quarter valued at about $154,732,000. IBM Retirement Fund increased its position in Bristol-Myers Squibb by 1.1% in the second quarter. IBM Retirement Fund now owns 219,448 shares of the biopharmaceutical company’s stock valued at $16,627,000 after buying an additional 2,421 shares during the last quarter. Essex Investment Management Co. LLC increased its position in Bristol-Myers Squibb by 0.3% in the second quarter. Essex Investment Management Co. LLC now owns 225,829 shares of the biopharmaceutical company’s stock valued at $16,610,000 after buying an additional 574 shares during the last quarter. HL Financial Services LLC increased its position in Bristol-Myers Squibb by 0.8% in the second quarter. HL Financial Services LLC now owns 360,221 shares of the biopharmaceutical company’s stock valued at $26,494,000 after buying an additional 2,901 shares during the last quarter. Finally, PGGM Investments increased its position in Bristol-Myers Squibb by 1.3% in the second quarter. PGGM Investments now owns 1,321,858 shares of the biopharmaceutical company’s stock valued at $97,223,000 after buying an additional 17,200 shares during the last quarter. 68.84% of the stock is owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.27% during mid-day trading on Tuesday, hitting $56.36. 9,818,891 shares of the stock were exchanged. Bristol-Myers Squibb Co. has a 52 week low of $49.03 and a 52 week high of $77.12. The firm has a market capitalization of $94.19 billion, a price-to-earnings ratio of 28.19 and a beta of 0.90. The company’s 50-day moving average price is $52.80 and its 200 day moving average price is $62.81.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.65 by $0.12. The business had revenue of $4.83 billion for the quarter, compared to analysts’ expectations of $4.76 billion. Bristol-Myers Squibb had a net margin of 18.54% and a return on equity of 28.98%. The business’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.39 EPS. Equities research analysts expect that Bristol-Myers Squibb Co. will post $2.85 EPS for the current year.
Several equities analysts recently commented on the company. SunTrust Banks Inc. downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $86.00 to $68.00 in a research note on Friday, August 5th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Citigroup Inc. dropped their price objective on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, August 3rd. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $65.00 price objective (down previously from $69.00) on shares of Bristol-Myers Squibb in a research note on Monday, August 8th. Finally, Deutsche Bank AG dropped their target price on Bristol-Myers Squibb from $68.00 to $62.00 and set a “hold” rating on the stock in a research report on Monday, August 8th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $67.51.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the business’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the sale, the director now owns 334,499 shares in the company, valued at approximately $19,022,958.13. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.24% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.